Aidoc Delivers the Most Comprehensive Neuroscience Package for AI-driven Coordination with New FDA 510(k) Clearance for Brain Aneurysm

End-to-end care coordination workflows tailored to radiologists, neuroendovascular surgeons and neurologists

Aidoc, the leading provider of healthcare AI solutions, announced today that it received its 9th FDA 510(k) clearance for triage and notification of brain aneurysm. This announcement further strengthens Aidoc’s position as the leading provider of the most comprehensive, enterprise-grade clinical AI platform, including the broadest neuroscience suite offered to clinicians around the world.

One out of 50 people suffer from a brain aneurysm in the U.S. each year. Overlooked 10 percent of the time, incidental positive cases often go unnoticed due to their small size and complexity of blood vessels in the brain. If ruptured, patients face a 50 percent chance of fatality. Adding to its repertoire of neuro solutions that include LVO (M1), ICH and C-spine fractures, Aidoc’s newly FDA-cleared solution now flags and communicates suspected positive cases of brain aneurysm.

The brain aneurysm solution delivers a care coordination workflow that is tailored to radiologists, neuroendovascular surgeons and neurologists, who need to treat multiple and different types of patients, whether from the emergency room, outpatients, at the hub, or transfered from the spoke.

“In the U.S., there is, tragically, a brain aneurysm rupture every 18 minutes. It’s an acute condition that can quickly turn fatal, so time is of the essence, especially for late night reading,” said Elad Walach, Co-founder and CEO of Aidoc. “We’re excited to include this algorithm in our set of neuro solutions, addressing the challenge of providing timely and accurate notifications of brain aneurysm cases. With this 9th FDA clearance in three years, we stay committed to providing the most comprehensive platform in the space.”

Aidoc’s AI platform enables seamless addition of new AI solutions as a native part of the workflow, eliminating the need to train current and new personnel as additional solutions are adopted by the hospital.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”